TX-COGNITE
17.1.2023 08:01:50 CET | Business Wire | Press release
Cognite, a global leader in industrial software, today announced B. Braun, a leading medical technology company, has selected Cognite Data Fusion® as the core of its Manufacturing Data Management solution. By integrating Cognite’s Industrial DataOps platform with its manufacturing domain knowledge, B. Braun leverages digital twins and AI-powered applications to achieve operational excellence across production, maintenance, and sustainability.
The Manufacturing Data Management solution will provide a fully digital DevOps workflow to develop, deploy, and sustain a pipeline of business applications. Cognite Data Fusion® will integrate and contextualize all operational data from product development, engineering, production, quality management, maintenance, EHS, and enterprise systems into one contextualized data layer that adheres to and extends industry standards for data modeling and enables the evolution of those data models over time as needed. The Manufacturing Data Management solution will provide comprehensive, easily accessible, and trusted information to both domain experts and developers, creating the foundation for data-driven transformation at scale.
Abram Ziegelaar, VP of Operational Technology at B. Braun Medical Industries in Malaysia, highlights three main value drivers of the solution:
"First, our wide variety of front-line workers and domain experts can collaborate with a common pool of trusted, real-world, live data from diverse sources and integrated, standardized applications. They get the information they need with the business context they need to respond quickly. This provides significant efficiency gains and reduces errors caused by poor quality or inaccessible information and disjointed processes.
"Second, our front-line people often intuitively know what needs to be done to improve performance, but lack the tools to test their intuition. Controlled access to a rich universe of well-curated information turns our front-liners into 'citizen data scientists' who can own their reports and analyses, make better decisions, and demonstrate the viability of improvement possibilities with real data. After implementation, we can measure the actual effects of improvements. Doing all of this in a global platform across many sites allows us to rapidly spread this knowledge and multiply the gains. 'Continuous Improvement' really becomes continuous.
"Third, you don't know what you don't know. A unique value of Cognite Data Fusion's AI-powered data contextualization is how it provides us with the 'smarts’ to answer very complex questions and create visibility into new areas to explore."
"On behalf of Cognite, we are proud to partner with B. Braun as they transform into a data-first organization based on a strong operational data foundation. Cognite Data Fusion®, which provides simple access to complex industrial data, will fast track time to value of the Manufacturing Data Management solution and empower B. Braun to build and scale valuable business solutions," said Petteri Vainikka, Chief Marketing Officer at Cognite.
As part of the partnership, Cognite will collaborate with B. Braun to integrate its in-house support tools with Cognite’s user community, Cognite Hub, to provide seamless support to the B. Braun organization. To learn more about Cognite Data Fusion, visit: cognite.com/en/product/cognite_data_fusion_industrial_dataops_platform
About B. Braun
As one of the world's leading medical technology companies, B. Braun protects and improves the health of people around the world. For over 180 years, the family-owned company has been accelerating progress in health care with pioneering spirit and groundbreaking contributions. This innovative strength continues to be the foundation of B. Braun's success today—always with the goal of improving clinical outcomes, cost of care, and patient benefits.
More than 66,000 employees live Sharing Expertise worldwide, they make B. Braun a true partner that develops smart solutions and sets new standards. By linking products, services, and consulting, the company improves treatment processes and supports medical staff. In doing so, B. Braun always acts with future generations in mind, which is why responsibility for sustainable growth is embedded into all business processes. In 2021, the B. Braun Group generated sales of € 7.9 billion. Visit us at www.bbraun.com.
About Cognite
Cognite is a global industrial SaaS company that was established with a clear vision: to rapidly empower industrial companies with open, contextualized, trustworthy, and accessible data to help drive the full-scale digital transformation of asset-intensive industries around the world. Our core Industrial DataOps platform, Cognite Data Fusion®, enables industrial data and domain users to collaborate quickly and safely to develop, operationalize, and scale industrial AI solutions and applications to deliver both profitability and sustainability. Visit us at www.cognite.com and follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005369/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom